2021
Genomic features of rapid versus late relapse in triple negative breast cancer
Zhang Y, Asad S, Weber Z, Tallman D, Nock W, Wyse M, Bey JF, Dean KL, Adams EJ, Stockard S, Singh J, Winer EP, Lin NU, Jiang YZ, Ma D, Wang P, Shi L, Huang W, Shao ZM, Cherian M, Lustberg MB, Ramaswamy B, Sardesai S, VanDeusen J, Williams N, Wesolowski R, Obeng-Gyasi S, Sizemore GM, Sizemore ST, Verschraegen C, Stover DG. Genomic features of rapid versus late relapse in triple negative breast cancer. BMC Cancer 2021, 21: 568. PMID: 34006255, PMCID: PMC8130400, DOI: 10.1186/s12885-021-08320-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultBiomarkers, TumorChemotherapy, AdjuvantDatasets as TopicDisease-Free SurvivalDNA Copy Number VariationsFemaleFollow-Up StudiesGene Expression ProfilingGene Expression Regulation, NeoplasticHumansLogistic ModelsMastectomyMiddle AgedModels, GeneticMutationNeoadjuvant TherapyNeoplasm Recurrence, LocalPrognosisRisk AssessmentTime FactorsTriple Negative Breast NeoplasmsConceptsLate relapseRapid relapseImmune signaturesBreast cancerAnti-tumor CD8 T cellsBackgroundTriple-negative breast cancerTriple-negative breast cancerCD8 T cellsTumor mutation burdenIndependent validation cohortNegative breast cancerFisher's exact testPearson's chi-squared testChi-squared testLogistic regression modelsLuminal signaturePrimary TNBCTNBC subsetImmune subsetsClinical featuresValidation cohortWhole-genome copy numberPrimary tumorM1 macrophagesT cells
2018
PD‐L1 expression and CD8‐positive T cells are associated with favorable survival in HER2‐positive invasive breast cancer
Hou Y, Nitta H, Wei L, Banks P, Lustberg M, Wesolowski R, Ramaswamy B, Parwani A, Li Z. PD‐L1 expression and CD8‐positive T cells are associated with favorable survival in HER2‐positive invasive breast cancer. The Breast Journal 2018, 24: 911-919. PMID: 30230111, PMCID: PMC6724200, DOI: 10.1111/tbj.13112.Peer-Reviewed Original ResearchConceptsPD-L1 expressionCD8-positive T cellsTumor-infiltrating lymphocytesHER2-positive casesLymph node metastasisCytotoxic immune reactionsBreast carcinomaImmune reactionsNode metastasisPD-L1Immune cellsConventional chemotherapyBreast cancerT cellsTissue microarrayHER2-positive invasive breast cancerHER2-positive invasive breast carcinomasHER2-positive breast cancerHER2-positive breast carcinomasTumor cellsPD1/PD-L1 expressionHigh Nottingham gradePD-L1 stainingInvasive breast cancerLower tumor stage
2017
Effect of neoadjuvant chemotherapy on immune checkpoint expression in breast cancer.
Stiff A, McQuinn C, Wesolowski R, Lustberg M, Reinbolt R, VanDeusen J, Sardesai S, Williams N, Noonan A, Dewani S, Ramaswamy B, Carson W. Effect of neoadjuvant chemotherapy on immune checkpoint expression in breast cancer. Journal Of Clinical Oncology 2017, 35: e12126-e12126. DOI: 10.1200/jco.2017.35.15_suppl.e12126.Peer-Reviewed Original ResearchNeo-adjuvant chemotherapyCD8 T cellsCD4 T cellsMore CD8 T cellsT cellsBreast cancerReceptor expressionCheckpoint inhibitorsCheckpoint expressionComplete pathologic response rateMore CD4 T cellsHormone receptorsPathologic response rateClinical stage IOperable breast cancerImmune checkpoint expressionReceptor expression changesBC subgroupsNeoadjuvant chemotherapyClinical responseProspective trialImmune checkpointsMedian agePD-1CTLA-4
2013
Human Vγ2Vδ2 T cells limit breast cancer growth by modulating cell survival‐, apoptosis‐related molecules and microenvironment in tumors
Aggarwal R, Lu J, Kanji S, Das M, Joseph M, Lustberg M, Ray A, Pompili V, Shapiro C, Das H. Human Vγ2Vδ2 T cells limit breast cancer growth by modulating cell survival‐, apoptosis‐related molecules and microenvironment in tumors. International Journal Of Cancer 2013, 133: 2133-2144. PMID: 23595559, PMCID: PMC3939063, DOI: 10.1002/ijc.28217.Peer-Reviewed Original ResearchConceptsΓδ T cellsVγ2Vδ2 T cellsT cellsApoptosis-related moleculesAntineoplastic effectsVγ2Vδ2 T-cell subsetTumor cellsInfiltration of tumorsMICA/BT cell subsetsHuman Vγ2Vδ2 T cellsBreast cancer growthExpression levelsInnate immune systemMolecular signalingBreast tumor cellsMDA-MB-231Resistant cell linesCell subsetsSurface expression levelsCancer growthImmune systemTumor growthMalignant transformationTumor progression
2012
Circulating CD68 positive (+) leukocytes in blood samples from patients (pts) with breast cancer (BC).
Lustberg M, Miller B, Wu Y, Xue W, Deighan C, Carothers S, Berger M, Shapiro C, Chalmers J. Circulating CD68 positive (+) leukocytes in blood samples from patients (pts) with breast cancer (BC). Journal Of Clinical Oncology 2012, 30: 172-172. DOI: 10.1200/jco.2012.30.27_suppl.172.Peer-Reviewed Original ResearchBlood samplesBreast cancerLeukocyte populationsPeripheral blood leukocyte populationsNegative depletionAdvanced breast cancerMultiparameter flow cytometry analysisVenous blood samplesBlood leukocyte populationsPrimary breast tumorsMacrophages/monocytesProgression of diseaseBreast tumor stromaCell surface markersAdditional phenotypic characterizationFlow cytometry analysisPositive leukocytesBC patientsPeripheral bloodPredictive markerPoor responseCD 68Such tumorsPatient's stageT cells